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Objective: The aim of this study was to ascertain the safety and efficacy of 
bronchial sleeve resection and reconstruction of the pulmonary artery in 
patients who had undergone induction chemotherapy for lung cancer. 
Methods: Between January 1991 and July 1996, we operated on 68 patients 
who had received three cycles of cisplatin-based induction chemotherapy. 
In 27 of these cases, we performed a lobectomy (n = 25) or bilobectomy 
(n = 2) associated with reconstruction of the bronchus, the pulmonary 
artery, or both. In only five additional patients, pneumonectomy had to be 
carried out. Before chemotherapy, 14 patients were in stage IIIA and 13 
were in stage IIIB. All patients in stage IIIB had T4 disease; no N3 cases 
were included. At thoracotomy, one patient had no evidence of tumor, six 
were in stage I, 13 were in stage II, six were in stage IIIA, and one was in 
stage IIIB. Sixteen patients had epidermoid carcinoma and 11 had adeno- 
carcinoma. Results: Sixteen patients underwent bronchial sleeve resection; 
11 had various types of pulmonary artery reconstruction, associated with 
the bronchial sleeve in eight cases. In 26 patients, resection was radical with 
histologically negative margins. Neither bronchial complications nor 
deaths occurred. One patient had empyema nd two had wound infections. 
Mean chest tube duration was 6 days. After a postoperative follow-up of 4 
to 69 months (mean 25 months), 14 patients are alive and free of disease, 
one is alive with disease, and 12 have died. There were no local recurrences. 
The 1- and 4-year survival rates are 78% and 39%, respectively. Conclusions: 
Although it is technically demanding, lobectomy associated with broncho- 
vascular reconstruction is feasible, with good immediate and long-term 
results, after induction chemotherapy. (J Thorac Cardiovasc Surg 1997; 
114:830-7) 
S leeve resection of the bronchus and pulmonary artery (PA) is a reliable procedure for radical 
resection of lung cancer 1' 2 when anatomically pos- 
sible. Patients who particularly benefit from this 
operation are those at a high risk for poor outcome 
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of pneumonectomy because of impaired respiratory 
or general status. Patients undergoing neoadjuvant 
therapy for stages I I IA and IIIB non-small-cell lung 
cancer often fall into this category; nevertheless 
about 50% 3, 4 are treated by pneumonectomy, with 
an overall increase in morbidity and mortality. 5 
After neoadjuvant therapy, pneumonectomy seems 
to be considered mandatory for radical treatment 
more often than in other settings. It is difficult to 
distinguish diffuse desmoplastic reaction and fibrosis 
related to chemotherapy from residual tumor. These 
abnormal tissues often surround the hilum and 
make the dissection extremely difficult. It is there- 
fore understandable that pneumonectomy ight be 
preferred to a bronchovascular reconstruction i a 
devascularized, fibrotic, and potentially tumor-con- 
taminated field. If tumor infiltration can be excluded 
by frozen-section analysis, however, a reconstructive 
operation of the bronchus, PA, or both associated 
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Table I. Case data 
Staging 
Age Follow-up 
No. Sex (yr) Pre Post Lung Resection Bronchus Artery Histology (rnos) 
1 F 45 IIIA II RUL S - -  Adeno 42, Dead 
2 M 59 IIIB II LUL S S Adeno 14, Dead 
3 F 57 IIIB II LUL S P Adeno 12, Dead 
4 M 53 IIIA II RUL + SVC S - -  Epi 7, Dead 
5 M 60 IIIA IIIA RUL S - -  Epi 10, Dead 
6 M 53 IIIA II RUMB S P Epi 45, Alive 
7 M 52 IIIB IIIB RUMB S P Adeno 8, Dead 
8 F 51 IIIB II RUL S - -  Epi 26, Dead 
9 M 54 IIIB IIIB RUL S P Epi 15, Dead 
10 M 60 IIIA I RUL S - -  Adeno 32, Dead 
11 M 64 IIIB II LUL - -  T Epi 34, Alive 
12 M 46 IIIA I RUL S - -  Epi 34, Alive 
13 F 45 IIIA IIIA LUL - -  P Adeno 24, Dead 
14 M 46 IIIB II RUL S - -  Epi 12, Dead 
15 M 64 IIIB 0 RUL" S - -  Epi 12, Alive 
16 M 59 IIIA I RUL - -  P Epi 37, Alive 
17 F 50 IIIB II RUL S - -  Epi 13, Alive 
18 M 54 IIIA I RUL S - -  Adeno 8, Alive 
19 M 60 IIIA II LUL S P Epi 46, Alive 
20 M 62 IIIB IIIA RUL S - -  Epi 69, Alive 
21 M 67 IIIA I RUL S - -  Adeno 36, Alive 
22 M 61 IIIB IIIA LUL S P Epi 19, Dead 
23 F 61 IIIB IIIA LUL S - -  Adeno 56, Alive 
24 M 61 IliA II RUL S - -  Adeno 47, Alive 
25 M 54 IIIB II RUL S - -  Adeno 8, Alive 
26 M 52 IIIB II RUL S - -  Epi 9, Alive 
27 M 50 IIIA II LUL S P Epi 4, Alive 
Pre, Before induction therapy; Post, after induction therapy; RUL, right upper lobectomy; S, sleeve; Adeno, adenocarcinoma; LUL, left upper lobectomy; P, 
pericardial patch; SVC, reconstruction of superior vena cava; Epi, Epidermoid carcinoma; RUMB, right upper-middle bilobectomy; T, pericardial tube. 
with lobectomy might  be an advantageous  a l terna-  
tive to pneumonectomy.  Few such operat ions  after 
neoad juvant  herapy appear  in the l i terature,  3'4, 6 
and  specific data on  per ioperat ive compl icat ions and  
survival rate are lacking. The  objective of this case 
series was to assess the surgical morta l i ty  and mor-  
bidity and  the oncologic  outcomes  of bronch ia l  and 
PA  reconstruct ions  after neoad juvant  chemother -  
apy. These f indings were also compared  with those 
of nonrandomized  contro l  pat ients  who underwent  
induct ion  chemotherapy  and s tandard  resection. 
Patients and methods 
Between January 1991 and July 1996, we operated on 
68 patients who had received three cycles of neoadjuvant 
chemotherapy for stage I I IA and IIIB non-small-cell lung 
cancer. The chemotherapy regimen consisted of cisplatin 
(120 mg/m2), mitomycin (2 mg/m2), and vinblastine (4 
rag/m2). 7 Our protocol did not include preoperative ra- 
diotherapy. Our study group consisted of 27 (39.7%) of 
these patients, who underwent a lobectomy or bilobec- 
tomy associated with a sleeve resection of the bronchus 
and/or the PA. We elected to use sleeve resection when- 
ever technically feasible; the following description of the 
patients' preoperative conditions and findings is a retro- 
spective analysis. 
Patients' data are reported in Table I. We operated on 
21 men and six women, ranging in age between 43 and 67 
years (mean 56 years). Before chemotherapy, 14 patients 
were in stage I I IA and 13 were in stage IIIB. Chest 
radiography, total-body computed tomography (CT) scan, 
and fiberoptic bronchoscopy were part of the noninvasive 
staging in all patients. Magnetic resonance imaging, bone 
scan, and percutaneous needle aspiration were performed 
in selected cases. The assessment of the cardiorespiratory 
status included spirometry, blood gas analysis, electrocar- 
diography, and echocardiography. Ventilation-perfusion 
lung scans, Holter monitoring, and stress testing were 
selectively performed in patients at risk. The complete 
clinical, radiologic, and functional workup was repeated 
before the operation. Eleven patients (40%) had a forced 
expiratory volume in 1 second of less than 40% of the 
predicted value after chemotherapy and were therefore 
considered poor candidates for pneumonectomy. Four 
additional patients (16%) had cardiac dysfunction that 
placed them at a high risk. In eight patients in stage I l iA, 
N2 disease was confirmed by mediastinoscopy; the re- 
maining six had clinically evident adenopathies. All pa- 
tients in stage IIIB had a T4 tumor infiltrating the 
mediastinum; six of them underwent video-assisted thora- 
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Fig. 1. Left upper lobe tumor surrounding the upper lobe 
bronchus and involving the PA to a variable extent. This is 
the typical setting in which bronchovascular reconstruc- 
tion is indicated. Note that the lingular artery can some- 
times be ligated separately. 
coscopy before chemotherapy, whereas CT or magnetic 
resonance imaging were considered sufficient for the 
staging purposes in seven cases. This introduces a poten- 
tial margin of error that will be eliminated by the devel- 
opment of precise chemotherapy staging guidelines. Six- 
teen patients had epidermoid carcinoma and 11 had 
adenocarcinoma. At thoracotomy one patient was in stage 
IIIB, five were in stage IIIA, 14 were in stage II, six were 
in stage I, and one had no histologic evidence of tumor. In 
the latter patient and in some patients in stage I, devas- 
cularized fibrotic tissue embedding the bronchus and the 
PA, rather than tumor infiltration, was the indication for 
sleeve resection. 
Patients were operated on within 3 weeks after comple- 
tion of chemotherapy (Fig. l). We performed 25 lobecto- 
mies and two bilobectomies. In 16 patients, the parenchy- 
mal resection was associated with a simple bronchial 
sleeve resection. In one case, we performed a bronchial 
sleeve and a PA sleeve (Fig. 2); in seven cases, the 
bronchial sleeve was associated with the reconstruction f
the PA defect by a pericardial patch (Fig. 3). In three 
patients, no bronchial sleeve was needed but a large PA 
defect was reconstructed with a pericardial patch (n = 2) 
or a pericardial conduit (n = 1; Fig. 2, C). In five patients 
undergoing upper sleeve lobectomy, the apical segmental 
bronchus of the lower lobe or the middle lobe bronchus 
was anastomosed separately to the main stem bronchus. 
All procedures were performed by the same surgical 
team according to the guidelines that we have reported 
elsewhere. TM Mediastinal dissection and radical hilome- 
diastinal lymphadenectomy were routinely performed, 
and all tissue margins (not only bronchial and arterial 
stumps) were carefully examined with frozen sections. The 
resection of subcarinal, paratracheal and hilar lymph 
nodes was carried out before the reconstruction, with the 
bronchial and PA stumps open in the operative field to 
obtain an easier access to these areas. Consequent skel- 
etonization of bronchial stumps was not considered a
problem. The bronchial anastomoses were performed 
with interrupted monofilament absorbable 4-0 sutures 
placed extramucosally and were wrapped with an inter- 
costal muscle flap as described elsewhere. ~2 PA sutures 
were performed with running 5-0 or 6-0 nonabsorbable 
monofilament sutures. Sutures were routinely performed 
by the aid of magnifying loupes. 
Systemic anticoagulation was initiated during operation 
(3000 to 5000 U heparin sodium not reversed by prota- 
mine sulfate at the end of the procedure) and maintained 
by subcutaneous injection of heparin (15,000 U/day) for 7 
to 10 days. Steroids were also routinely administrated in
the perioperative period. A 10 mg dose of intravenous 
methylprednisolone was administrated during operation. 
From the first postoperative day, 10 mg methylpred- 
nisolone was administrated aily intramuscularly until 
oral feeding was resumed. Subsequently, the dose was 
tapered to 4 mg orally twice a day until postoperative day 
10. All patients were extubated in the operating room at 
the end of the procedure. Vigorous physiotherapy was 
started on the first postoperative day, and aspiration of 
secretions was performed by fiberoptic bronchoscopy 
when needed. Routine bronchoscopies were performed at 
the end of the surgical procedure, before discharge from 
the hospital, and after 1 and 6 months. Preliminary 
estimates of survival rate were calculated by means of the 
Kaplan-Meier product-limit method. ~3 
Results 
Twenty-six of 27 patients underwent radical resec- 
tion with histologically negative resection margins. 
One patient had an infiltrative paratracheal mass 
that could not be totally resected. The lesion was 
separated from the hilum, and pneumonectomy 
would not have been beneficial in providing radical 
treatment. The patient had postoperative empyema 
and could not undergo adjuvant herapy because of 
compromised general status; he later had bone 
metastases and died 8 months after the operation. 
Neither bronchial nor vascular complications oc- 
curred. One patient had empyema and two had 
infection of the thoracotomy wound. Twelve pa- 
tients had air leaks for longer than 7 days; mean 
chest tube duration was 6 days (4 to 15 days). Twelve 
patients required at least one early postoperative 
bronchoscopy for aspiration of secretion causing 
atelectasis or for a check of the anastomosis. Among 
the 41 patients who underwent induction chemo- 
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Fig. 2. Left upper lobectomy associated with a double sleeve resection of the bronchus and PA. A, The 
bronchial anastomosis has been performed with interrupted sutures. The proximal stump of the PA is clamped, 
and the distal stump lies open in the operative field. B, If the two ends of the PA can be brought together, an 
end-to-end anastomosis can be performed with a running suture. C, If the two ends of the PA cannot be brought 
together, the vessel is reconstructed with a conduit obtained by folding a rectangular patch of autologous 
pericardium. Note the site where the pericardium was harvested from the pericardial sac. 
therapy and standard resection, there were two 
bronchopleural fistulas after pneumonectomy (with 
one death) and one acute myocardial infarction. 
The incidence of postoperative air leaks, the of chest 
tube duration, and the need for bronchoscopic 
aspiration of secretions did not vary from the exper- 
imental series. Twelve patients underwent postop- 
erative adjuvant therapy with no problems. No 
patient had respiratory insufficiency necessitating 
oxygen supplementation for longer than 3 days after 
the operation. Postoperative follow-up ranged be- 
tween 4 and 69 months. Fourteen patients are alive 
and free from tumor 4 to 69 months after the 
operation. One patient is alive with distant metas- 
tases. Twelve patients died 7 to 42 months after the 
operation; six died of distant metastases and six of 
neoplastic cachexia. There were no local recur- 
rences in the airway. The 1- and 4-year survival rates 
for the sleeve resection group were 78% and 39%, 
respectively. The 1- and 4-year survival rates for 
patients who underwent induction chemotherapy 
and standard resection were 65% and 36%, respec- 
tively, with no statistically significant difference from 
the experimental series. 
Comment 
Neoadjuvant chemotherapy, or chemotherapy-ra- 
diotherapy followed by surgical treatment, is evolv- 
ing as an effective treatment modality for locally 
advanced lung cancer. Multimodal therapy increases 
survival, but its aggressiveness exposes patients to a 
variety of complications. These can occur during or 
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Fig. 3. If the tumor does not infiltrate the full circumfer- 
ence of the PA, a partial resection of the vessel can be 
performed (A). The artery is reconstructed with a patch of 
autologous pericardium (B). 
after the induction regimen, before or after the 
operation. Surgeons who deal with these patients 
are aware that the operation is often technically 
demanding and that a morbidity rate around 30% 
should be expected. Some trials employ chemother- 
apy alone, 3 others consist of chemotherapy lus 
radiotherapy, e, 14 but an increased complication rate 
is constantly reported. Also, these data do not 
change when trials reporting on stages IliA or IIIB 
are considered. The ubiquitous increase in compli- 
cations and mortality rate, although evenly distrib- 
uted by treatment modality and eligibility criteria, is 
not unexpectedly more evident in association with 
pneumonectomy.S, is As pointed out by Rush and 
Benfield, 15 the potential high risk of pneumonec- 
tomy is important because between 27% and 
56%3, 4, 6 of patients receiving neoadjuvant therapy 
require pneumonectomy. In fact, these patients usu- 
ally have infiltrative centrally located lesions (Te) or 
extended hilomediastinal (often extracapsular) 
lymphadenopathies. We do not at present have a 
pathophysiologic explanation for the increased risk 
of pneumonectomy in these patients, and that would 
be far beyond the purposes of our report. However, 
assuming that the risks of pneumonectomy cannot 
be avoided, we wondered whether the need for 
pneumonectomy could be reduced while maintain- 
ing the same rates of radical treatment and survival. 
The results of our study indicate that bronchovas- 
cular reconstructive surgery is an effective alterna- 
tive to pneumonectomy after neoadjuvant therapy. 
Despite what may have been feared so far, in our 
patients the surgical complications were reduced 
and the radical nature of treatment and survival 
were not jeopardized. Overall, we have operated on 
68 patients after chemotherapy; it is noteworthy that 
only in five cases (7.3%) were we obliged to perform 
a pneumonectomy. This rate is lower than those 
reported by Sugarbaker and coworkers 6 (27%), 
Rush and colleagues 4 (31%), Fowler and associates 5 
(53.8%), and Rosell and colleagues 3 (56%). In our 
27 patients undergoing bronchovascular reconstruc- 
tive operations, the radical nature of treatment was 
not reduced by the less extended resection: only one 
patient (4%) had nonradical resection. Our series 
included no local recurrences in the airway, but one 
patient did have a mediastinal relapse of disease 
(4%). The 1- and 4-year survival rates compare 
favorably with those of major series in the litera- 
ture.3, 4, 6 Our series was small, however, and it is not 
intended as a follow-up study on neoadjuvant ther- 
apy. Also, we studied a selected subset of patients, 
and survival rates should be more correctly com- 
pared with those of patients undergoing radical 
resection rather than with the overall survival rates 
of other series. We are satisfied that from this point 
of view our results are similar to those reported in 
the literature. 3' 4, 6 
The technical aspects of sleeve resection after 
neoadjuvant therapy have not yet been addressed in
detail. The deleterious effects of chemotherapy and 
especially radiotherapy on bronchial healing are 
well known, and this may have deterred more ex- 
tended use of sleeve resection. In addition, all lung 
resections after induction therapy are technically 
demanding, and a complex bronchovascular recon- 
structive procedure is even more so. The risk of 
anastomotic disruption was a serious concern at the 
beginning of our experience. Our protocol, however, 
does not include preoperative radiotherapy, and 
Sugarbaker and colleagues 6 did not report an in- 
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creased incidence of bronchopleural fistulas in their 
series of patients who received chemotherapy alone. 
Our previous experience 8 and our positive initial 
results encouraged us to proceed and led to the 
results that we report here. The procedure is gener- 
ally more difficult than in other settings because of 
the diffuse desmoplastic reaction that is almost 
constantly present in the hilum and mediastinum. 
Also, the extent of the bronchial or PA resection was 
longer than in other cases: in five patients, we 
anastomosed the apical segmental bronchus of the 
lower lobe and the middle lobe bronchus separately 
to the main stem bronchus. In addition, a complex 
reconstruction of the PA is frequently required 
(40% of cases) in association with the bronchial 
procedure, further complicating the operation. We 
believe that a number of technical points are crucial 
for success. (1) The surgical dissection should be 
accurate, and frozen sections of all resection mar- 
gins should be examined. (2) If the bronchus is 
encased in stiff, fibrotic tissue, even without evi- 
dence of malignancy, the sleeve should be extended 
to reach healthy tissue. (3) The bronchial suture 
should be protected by well-vascularized tissue 12' 16 
(intercostal muscle flap). (4) Low-dose steroids 
should be administered to reduce anastomotic 
edema. We noted a certain difficulty in the reexpan- 
sion of lung parenchyma nd the sealing of air leaks. 
This led to delayed chest tube withdrawal and 
prolonged hospital stay. We attribute this problem 
to the increased stiffness and fragility of the lung 
parenchyma as a result of chemotherapy. In fact, 
chemotherapy may have an impact on the lung 
interstitium and mediastinal ymphatic drainage, 15 
damaging the lung parenchyma and increasing the 
risk of postoperative adult respiratory distress syn- 
drome. 5 This consideration, however, should apply 
more to pneumonectomy than to sleeve resection, 
where more lung parenchyma is preserved. We did 
not observe episodes of postoperative respiratory 
insufficiency among our patients. 
We conclude that a bronchovascular reconstruc- 
tive procedure yields less morbidity and mortality, 
with radical treatment and survival rates similar to 
those of pneumonectomy in patients undergoing 
preoperative chemotherapy. It can therefore be 
considered the procedure of choice when feasible in 
this setting as in other fields of pulmonary surgery. 
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Discussion 
Dr. Jean Deslauriers (Sainte-Foy, Quebec, Canada). I
thank the program committee for giving me the opportu- 
nity to discuss this important, well-presented article. Ap- 
proximately 3 weeks ago, the American Surgical Associa- 
tion held its annual meeting in Quebec City, and we had 
the privilege of having Drs. Harold Urschel and Fred 
Grover at our hospital to make rounds with the residents. 
I presented the case of a 52-year-old man with a right 
upper lobe carcinoma in whom we had done induction 
chemotherapy because of a positive level-10 node discov- 
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ered at mediastinoscopy. The chemotherapy used was 
the cisplatin-mitomycin-vinblastine combination you de- 
scribed. At the time of operation, a sleeve resection would 
have been feasible, but I believed that pneumonectomy 
would achieve better tumor clearance because the patient 
had residual nodal disease at the hilum. 
The patient did well for about 72 hours after the 
operation, but then the classic picture of postpneumonec- 
tomy edema developed and the patient required intuba- 
tion and mechanical ventilation. This man was fortunate, 
because during the next week both the clinical picture and 
chest radiograph improved, and we were able to wean him 
from the respirator. 
During the ensuing discussion, Dr. Urschel, with his 
wisdom and experience, taught me three important les- 
sons. The first is that "pneumonectomy is a disease" in 
itself, and that it should be avoided at all cost. The second, 
but no less important, lesson is that pneumonectomy is 
seldom indicated for nodal disease alone, because sleeve 
resection can be as complete an operation without the 
increased mortality rate associated with pneumonectomy. 
He finally mentioned some of the long-term complica- 
tions, such as late pulmonary hypertension or respiratory 
failure, sometimes associated with pneumonectomy but 
seldom seen after lobectomy or sleeve lobectomy. 
A few years ago, Dr. Ginsberg reported that the mod- 
ern operative mortality rate related to pneumonectomy 
was 6.2%, a number derived from cases done by Lung 
Cancer Study Group surgeons, all of whom were experi- 
enced thoracic surgeons. As you mentioned, it is likely 
that in the neoadjuvant setting--whether chemotherapy, 
radiation therapy, or both--this operative mortality rate 
will rise to 8% to 10%. 
You present data suggesting that sleeve resection with 
or without PA reconstruction ot only is technically 
feasible after neoadjuvant chemotherapy but, when done 
properly, is also associated with low morbidity and accept- 
able short-term and midterm survival rates. This is an 
important ake-home message that is likely to affect the 
practice of all thoracic surgeons involved in this type of 
work. 
I have three questions. First, how do you explain the 
high probability of sleeve resection in this specific popu- 
lation when in general most centers perform sleeve resec- 
tions in only about 5% of all patients undergoing pulmo- 
nary resection for lung cancer? 
Second, in light of the relative mediocrity of CT scan- 
ning and MR imaging in accurately predicting nodal 
metastases or mediastinal invasion, do you consider me- 
diastinoscopy, which was performed in only eight of your 
cases, important in selecting patients for neoadjuvant 
treatment protocols? 
Finally, do you have data supporting the routine use of 
steroids during the immediate postoperative p riod? 
Dr. Hermes C. Grillo (Boston, Mass.). I think this is an 
impressive piece of work, and I congratulate you. May I 
bring up one small technical point with which you had no 
trouble, just to warn you for the future? 
I believe you said that you wrapped the anastomoses 
with intercostal muscle, which is an excellent echnique 
generally, except if you use it as a circumferential wrap. 
Sooner or later yon will end up with a grommet of bone 
formed from the periosteum. This is extremely difficult o 
avoid, because if you try to trim the periosteum off, you 
endanger the intercostal vessel. I only say this because I 
used this muscle for a good many years in tracheal work 
and then, having had such a grommet, which led to a 
terrible problem of secondary surgery for obstruction, I 
abandoned the intercostal muscle and have since used 
other things for wrapping, such as pericardial fat. Another 
surgeon once told me about a case that he had, so 
although it will not happen often, when it does happen, it 
is disastrous. 
Dr. Alexander G. Patterson (St. Louis, Mo.). Could you 
comment on the exposure you used? Was thoraeotomy 
performed in all patients, or did you use sternotomy, 
particularly in those patients who were in stage IIIB 
before the operation? 
Dr. Rendina. I thank all discussants for their comments 
and questions. I will try to answer all the questions in 
order. 
In response to Dr. Deslauriers's questions about the 
percentage of sleeve resections in our practice, we started 
to do sleeve resections extensively in 1989. "Extensively" 
means that we elected to do sleeve resection whenever it 
was technically possible and oncologically safe. In the 
period between 1989 and 1997, we did 104 sleeve resec- 
tions, compared with approximately 200 cases per year of 
major pulmonary resection currently performed at our 
institution. I do not have the totals, but that may give you 
an idea of the percentage. 
We ourselves were impressed by the frequency with 
which sleeve resection might be the most appropriate way 
to treat patients who had neoadjuvant chemotherapy. 
Because of the shrinkage of the tumor and because of the 
fibrosis that surrounds the bronchus and PA, we have 
pointed out in our article that at least four of our cases did 
not have tumor infiltration of the bronchus necessitating 
sleeve resection for strict oncologic reasons. The reason 
we performed this operation was that the situation of 
benign fibrosis surrounding the bronchus was such that a 
pneumonectomy would have been otherwise indispens- 
able. I hope that answers your question. 
The second question concerns mediastinoscopy. We 
have the attitude at our institution that mediastinoscopy is 
performed only in selected N2 cases. When we see 
patients with clinical N2--that is, CT evidence of medias- 
tinal involvement causing clinical symptoms such as supe- 
rior vena eava syndrome, direct infiltration of the airway 
detectable by bronchoscopy, or recurrent laryngeal nerve 
paralysis--we do not perform mediastinoscopy. We be- 
lieve that this would be overstaging. 
As far as steroids are concerned, our point of view is 
reported in a study that was published a few years ago. 1° 
That was a clinical study on 20 patients undergoing sleeve 
resection; 10 of them had steroids in the perioperative 
period and 10 did not. They were randomly assigned, and 
although the number was small, the results of that study 
clearly indicated that steroids in the perioperative period 
were effective in reducing the edema around the anasto- 
mosis, ultimately decreasing the complication rate and 
improving the outcome. 
We were also advised to consider the administration of
steroids by Dr. Couraud, who as many of you know has 
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been a pioneer in laryngotracheal reconstructions in Eu- 
rope. He indicated that the use of steroids in the preop- 
erative period was effective and safe even in that much 
more difficult setting. 
Dr. Grillo, I am honored by your interest in our work, 
and I will just tell you that we have been using the 
intercostal muscle for a long time. At the beginning of our 
experience, we used silver nitrate to try to either delay or 
annul reossification, but in the last few years, we have not 
used it and have not had any problems. 
Dr. Patterson, it is our privilege to have you discuss our 
article. We operated on all of these patients through 
thoracotomies. We think that this is a much easier means 
of access, although we have employed median sternotomy 
in three patients in another series who needed reconstruc- 
tion of the PA under cardiopulmonary b pass. In this 
series, we employed only thoracotomy. 
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